Structure Therapeutics Inc. (GPCR)

NASDAQ

$64.84

-$2.22 (3.31%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$64.50$68.47

Open $67.08

52 Week Range

$13.22$94.90

Previous Close $67.06

Market Cap3.73B

Volume1.05M

Avg Volume1.47M

P/E (TTM)-6.94

EPS (TTM)$-9.34

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Structure Therapeutics Inc.

DEC112025

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Source: GlobeNewsWire•4 days ago

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today an...

DEC92025

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Source: GlobeNewsWire•6 days ago

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today an...

DEC82025

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Source: GlobeNewsWire•7 days ago

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today an...

DEC82025

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Source: GlobeNewsWire•8 days ago

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation...

DEC72025

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Source: GlobeNewsWire•8 days ago

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today an...

NOV62025

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Source: GlobeNewsWire•39 days ago

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025...

Latest Press Releases for Structure Therapeutics Inc.

DEC112025

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Source: GlobeNewsWire•4 days ago

DEC92025

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Source: GlobeNewsWire•6 days ago

DEC82025

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Source: GlobeNewsWire•7 days ago

DEC82025

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Source: GlobeNewsWire•8 days ago

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation...

DEC72025

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Source: GlobeNewsWire•8 days ago

NOV62025

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Source: GlobeNewsWire•39 days ago

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025...